[The use of cardiac glycosides in therapeutic practice (a review of the literature)]. 1994

M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba

UI MeSH Term Description Entries
D002301 Cardiac Glycosides Cyclopentanophenanthrenes with a 5- or 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. Plants they come from have long been used in congestive heart failure. They increase the force of cardiac contraction without significantly affecting other parameters, but are very toxic at larger doses. Their mechanism of action usually involves inhibition of the NA(+)-K(+)-EXCHANGING ATPASE and they are often used in cell biological studies for that purpose. Cardiac Glycoside,Cardiotonic Steroid,Cardiotonic Steroids,Glycoside, Cardiac,Glycosides, Cardiac,Steroid, Cardiotonic,Steroids, Cardiotonic
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications

Related Publications

M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
November 1958, Triangle; the Sandoz journal of medical science,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
July 1990, Vrachebnoe delo,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
January 1977, Farmakologiia i toksikologiia,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
August 1979, Die Pharmazie,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
January 1972, Terapevticheskii arkhiv,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
September 1960, Gazzetta medica italiana,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
June 2021, Journal of clinical pharmacy and therapeutics,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
April 1983, Die Medizinische Welt,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
March 1952, American journal of pharmacy and the sciences supporting public health,
M D Neporadnyĭ, and V H Denysiuk, and M A Mazepa, and N S Vatseba
December 1964, Die Pharmazie,
Copied contents to your clipboard!